skip to content

Committee for ICSA Shanghai

Dejun Tang (Chair, Novartis, China, dejun.tang@novartis.com, 10/2013 10/2016)

Zhi Geng (Peking University, 10/2013 – 10/2016), Chen Yao (Peking University, 10/2013 – 10/2016),  Wei Yuan (Renmin University of China, 10/2013 – 10/2016), Qihua Wang (Chinese Academy of Sciences, 10/2013 – 10/2016), Guohua Zou (Chinese Academy of Sciences, 10/2013 – 10/2016), Hengjian Cui (Capital Normal University, 10/2013 – 10/2016), Zhaojun Wang (Nankai University, 10/2013 – 10/2016), Xiaolong Pu (East China Normal University, 10/2013 – 10/2016), Ming Zheng (Fudan University, 10/2013 – 10/2016), Naiqing Zhao (Fudan University, 10/2013 – 10/2016), Yong Zhou (Shanghai University of Finance and Economic, 10/2013 – 10/2016), Dong Han (Shanghai Jiao Tong University, 10/2013 – 10/2016), Huazhen Lin (Southwestern University of Finance and Economics, 10/2013 – 10/2016), Xueqin Wang (Sun Yat-sen University, 10/2013 – 10/2016), Feng Chen (Nanjing Medical University, 10/2013 – 10/2016), Jielai Xia (The Fourth Military Medical University, 10/2013 – 10/2016), Roger Qu (Pfizer, China, 10/2013 – 10/2016), Wei Zhang (Boehringer-Ingelheim, China, 10/2013 – 10/2016), Jie Chen (Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd., 10/2013 – 10/2016), Bill Wang (Merck, China, 10/2013 – 10/2016), Yanping Wang (Eli Lilly and Company, China, 10/2013 – 10/2016), Ouhong Wang (Amgen, China, 10/2013 – 10/2016), Jun Shao (University of Wisconsin/East China Normal University, 10/2013 – 10/2016), Dongchu Sun (University of Missouri/ East China Normal University, 10/2013 – 10/2016), Ming-Hui Chen (Ex-Officio, 2013), Shu-Yen Ho (Ex-Officio, 2013), Ying Lu (Ex-Officio, 2014), Zhezhen Jin (Ex-Officio, 2013-2016), Wei Shen (Ex-Officio, 2015)